ZM 241385

Drug Profile

ZM 241385

Latest Information Update: 06 Sep 2000

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antihypertensives; Neuroprotectants; Nootropics; Vasodilators
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Angina pectoris; Cognition disorders; Neuroprotection

Most Recent Events

  • 06 Sep 2000 Discontinued-Preclinical for Neuroprotection in United Kingdom (Unknown route)
  • 06 Sep 2000 Discontinued-Preclinical for Cognition disorders in United Kingdom (Unknown route)
  • 06 Sep 2000 Discontinued-Preclinical for Angina pectoris in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top